Aspirin Use Not Tied to Clinical Outcomes in Nonobstructive CAD
Statin use linked to reduced risk for major adverse cardiovascular events in individuals with nonobstructive coronary artery disease
Angina
Possible Defective Delivery System Prompts Recall of Nitroglycerin Lingual Spray
Nitroglycerin Lingual Spray is indicated for the acute relief of an attack or prophylaxis of chest pain due to coronary artery disease in adult patients.
Guideline Addresses Diagnosis, Evaluation of Chest Pain in Adults
Chest pain can extend beyond the chest; patients experiencing chest pain or equivalent should seek medical help immediately
Katerzia, an Oral Suspension Formulation of Amlodipine, Now Available
Katerzia Oral Suspension, 1mg/mL is now commercially available, according to Azurity Pharmaceuticals.
Does Ranolazine Potentiate the Effects of ACE Inhibitors, Angiotensin Receptor Blockers?
According to the results of a study reanalyzing data obtained from an FDA review, , ranolazine potentiates the effects associated with ACE inhibitors, as well as angiotensin receptor blockers.
FIRST-Metoprolol Unit-of-Use Compounding Kit Now Available
Metoprolol tartrate is indicated for the treatment of hypertension, for the long-term treatment of angina pectoris, and for the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality.
Kapspargo Sprinkle Available to Treat Hypertension, Angina, Heart Failure
For patients unable to swallow an intact capsule, the pellets can be sprinkled over soft food (eg, applesauce, yogurt, pudding) or given via a nasogastric (NG) tube.
Outcomes-Based Pricing Doesn’t Cut Costs of PCSK9 Inhibitors
“Although outcomes-based pricing may have a role in other settings, our analysis of its application to PCSK9 inhibitors – effective preventive medications with a high price tag – shows the potential limitation of this approach for high-cost preventive therapies,” the authors write.
First PCSK9 Inhibitor Gets FDA Approval for MI, Stroke Prevention
Repatha reduced the risk of heart attack by 27%, the risk of stroke by 21% and the risk of coronary revascularization by 22%.
Landmark Study Questions Efficacy of Stenting in Stable Angina
ORBITA was a double-blind, randomized controlled trial that evaluated PCI vs. a placebo procedure for improved exercise capacity in patients with severe coronary disease who were receiving optimum medical therapy.
